Your Source for Venture Capital and Private Equity Financings

VC-funded Company:

Sitari Pharmaceuticals
11099 North Torrey Pines Road, Suite 290
La Jolla, CA 92037
Phone: 858-750-4700
www.coipharma.com/portfolio/sitari-pharma

Sitari Pharmaceuticals is targeting the Transglutaminase 2 (TG2) pathway for the development of treatments for multiple disease indications, with an initial focus in celiac disease. Celiac disease is an autoimmune digestive disease caused by intolerance to gluten, a protein found in wheat, rye and barley that damages the small intestine and interferes with absorption of nutrients from food. The company's therapeutic approach targets TG2, an enzyme that is thought to play a multi-factorial role in celiac disease. Sitari was founded based on intellectual property in-licensed from the laboratory of Chaitan Khosla, Ph.D., professor of Chemical Engineering and Chemistry at Stanford University and Director of the Stanford Institute for Chemical Biology, and a scientific founder of Sitari.

Key Contact
Name
Chaitan Khosla
Title
Scientific Founder
E-Mail
Funding Events

Date
Amount
Type
Investors
Valuation
11/22/13 $10,000,000 Series A Avalon Ventures
GlaxoSmithKline
undisclosed